HLS Therapeutics (TSE:HLS) Hits New 12-Month High - What's Next?

Key Points

• HLS Therapeutics Inc. shares reached a new 52-week high of C$5.48 during trading, closing at C$5.10.
• The company has a market capitalization of C$114.80 million and a price-to-earnings ratio of -5.17.
• HLS Therapeutics specializes in the acquisition and commercialization of branded pharmaceutical products, particularly for central nervous system and cardiovascular treatments.

Shares of HLS Therapeutics Inc. (TSE:HLS - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as C$5.48 and last traded at C$5.10, with a volume of 4686 shares changing hands. The stock had previously closed at C$5.16.

Analysts Set New Price Targets

Separately, Raymond James Financial raised HLS Therapeutics from a "hold" rating to a "moderate buy" rating and raised their price target for the stock from C$5.00 to C$6.00 in a report on Thursday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, HLS Therapeutics presently has an average rating of "Hold" and a consensus target price of C$5.00.

HLS Therapeutics Price Performance

The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The company has a 50-day simple moving average of C$4.96 and a 200-day simple moving average of C$4.61. The company has a market cap of C$116.13 million, a price-to-earnings ratio of -5.23 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.